Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Woolsey Pharmaceuticals Inc. is active in the Biotechnology & Pharmaceuticals technology area with 5 pending office actions. These actions are distributed across 5 distinct examiners, which means each pending application is being reviewed by a different individual. This variety of examiners can lead to different prosecution experiences for each matter in the portfolio.
The portfolio's work is spread across 2 distinct art units. This indicates that the company's pharmaceutical innovations are diverse enough to be categorized into two different technical areas by the patent office. WITHERSPOON, SIKARL A is the busiest examiner for the portfolio, with 1 pending office action. This examiner's workload is one of five equal parts of the total pending actions.
The workload is evenly balanced, as the busiest examiner is responsible for 1 of the 5 total pending actions. This distribution ensures that no single examiner has a dominant influence on the portfolio's progress. Practitioners should be prepared to navigate the requirements of 2 distinct art units and the individual styles of five separate examiners. This structure requires a flexible strategy to manage the different technical and examiner-specific demands.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WITHERSPOON, SIKARL A | 1 | 86.2% | -20.1% |
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
| RAMOS LEWIS, JOSMALEN MILAGROS | 1 | 53.6% | +23.9% |
| BAUER, NICOLA MARIA | 1 | 58.3% | +50.0% |
| SCHMITT, MICHAEL J | 1 | 56.8% | +20.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837780 | TASTE-MASKING ORAL FORMULATIONS OF FASUDIL | WITHERSPOON, SIKARL A | — |
| 18712654 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | HABTE, KAHSAY | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18665262 | METHODS OF TREATING FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS BY ORAL ADMINISTRATION OF FASUDIL | RAMOS LEWIS, JOSMALEN MILAGROS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005269 | METHODS OF TREATING PROTEINOPATHIES | SCHMITT, MICHAEL J | 154d overdue |
| 18300445 | METHODS OF TREATING CORTICAL DEMENTIA ASSOCIATED WANDERING | BAUER, NICOLA MARIA | 59d overdue |
| 18665262 | METHODS OF TREATING FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS BY ORAL ADMINISTRATION OF FASUDIL | RAMOS LEWIS, JOSMALEN MILAGROS | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837780 | TASTE-MASKING ORAL FORMULATIONS OF FASUDIL | WITHERSPOON, SIKARL A | — | DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18712654 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | HABTE, KAHSAY | — | DP | Non-Final OA | — | Pending | May 22, 2024 |
| 18665262 | METHODS OF TREATING FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS BY ORAL ADMINISTRATION OF FASUDIL | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §102§103 | Non-Final OA | — | Pending | May 15, 2024 |
| 18300445 | METHODS OF TREATING CORTICAL DEMENTIA ASSOCIATED WANDERING | BAUER, NICOLA MARIA | 1621 | §103 | Final Rejection | 59d overdue | Pending | Apr 14, 2023 |
| 18005269 | METHODS OF TREATING PROTEINOPATHIES | SCHMITT, MICHAEL J | 1629 | §102§103DP | Final Rejection | 154d overdue | Pending | Jan 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial